"HRT's Role in Women's Aging and Healthspan"

Hormone Replacement Therapy (HRT) has emerged as a promising intervention with geroprotective potential, particularly for women navigating the complexities of aging. A review of literature highlights the importance of timing in the initiation of HRT, suggesting that it may offer protective benefits against various aging processes. Nevertheless, careful consideration of individual health profiles and potential risks is critical for personalized treatment strategies.

The Geroprotective Potential of Hormone Replacement Therapy

Date: January 14, 2026

HRT has been recognized not only for its role in alleviating menopausal symptoms but also as a potential strategy for extending the healthspan of women. However, its application is not universally recommended, particularly for women with specific medical conditions. The ongoing research emphasizes the necessity for personalized approaches and improved diagnostic criteria to tailor hormone replacement therapy effectively (1).

Sex-specific Aging Trajectories

Aging trajectories differ significantly between sexes, primarily due to hormonal influences and reproductive organ aging. The authors of this review have provided detailed discussions on these differences, asserting that the decline in female reproductive capabilities—characterized by reduced estrogen and progesterone production—occurs earlier in life and accelerates various aging processes.

The impact of estrogens and progesterone extends beyond the reproductive system; their withdrawal can precipitate serious health issues, including:

• Osteoporosis: Increased risk due to bone density loss.
• Sarcopenia: The progressive loss of muscle mass.
• Cardiovascular Disease: Heightened risk associated with hormonal fluctuations.
• Metabolic Syndrome: A constellation of conditions that increase the risk for heart disease and diabetes.
• Cognitive Impairment: Decline in memory and cognitive functioning.
• Unpleasant symptoms: Such as hot flashes and sleep disturbances.

This multifaceted hormonal influence significantly informs the rationale for considering HRT as a geroprotective intervention.

More Than Managing Symptoms

While HRT is typically prescribed to mitigate the symptoms associated with menopause, evidence suggests its potential utility as a proactive geroprotective strategy, particularly for healthy mid-life women regardless of symptom status.

The molecular roles of estrogen and progesterone indicate their involvement in various "hallmarks of aging," which suggests that their replacement could help counteract the adverse effects related to hormonal withdrawal. Specific benefits of estrogens include:

Similarly, progesterone has shown to play a role in:

• Modulating autophagy, a process that cleans up cellular debris.
• Maintaining hormonal balance and immune function.
• Supporting tissue regeneration and stem cell health.

Weighing Risks and Benefits

Beyond molecular interactions, research highlights the systemic geroprotective effects of HRT, including:

While these beneficial effects signal a need to revisit clinical guidance on HRT, it is crucial to recognize that certain risks remain. For instance, HRT has been associated with an increased risk of venous thromboembolism (VTE), particularly with oral estrogen preparations. Furthermore, the timing of initiation is critical; initiating therapy more than 10 years post-menopause may elevate the risks of stroke and cardiovascular events (8).

Personalizing the Approach

To optimize the risk-benefit ratio for HRT, the authors propose categorizing women into three distinct groups:

1. Low-Risk Group: Women under 60, less than 10 years post-menopause, with a BMI under 30, no cardiovascular diseases, and non-smokers.
2. Intermediate-Risk Group: Women who may require a personalized approach with monitoring, possibly due to mild metabolic syndrome or a family history of cardiovascular disease.
3. High-Risk Group: Women with prior VTE, stroke, active malignancies, or uncontrolled cardiovascular diseases should avoid HRT.

The authors suggest integrating aging-related biomarkers, such as:

• Epigenetic clocks
• Inflammatory markers
• Metabolic indicators
• Cardiovascular health metrics
• Bone turnover markers
• Neurocognitive and sleep indicators

This integrative approach, using multi-biomarker data rather than relying on single metrics, could enhance the personalization of HRT.

Future Directions

Looking ahead, larger trials are needed to explore these trajectories and personalized strategies for HRT. Combining HRT with other geroprotective therapies might further enhance outcomes.

In conclusion, while HRT holds promise as a geroprotective strategy for enhancing women's health during aging, the complexities of its application necessitate a personalized approach that prioritizes safety and effectiveness.

Literature

[1] Rabinovici, J., et al. (2025). Perimenopausal Hormone Replacement Treatments as a Geroprotective Approach – Adapting Clinical Guidance. Aging and disease, 10.14336/AD.2025.1391.

[2] Dong, L., et al. (2023). Unraveling female reproductive senescence to enhance healthy longevity. Cell research, 33(1), 11–29.

[3] Hodis, H. N. & Mack, W. J. (2014). Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. The Journal of steroid biochemistry and molecular biology, 142, 68–75.

[4] Mosekilde, L., et al. (2000). Hormonal replacement therapy reduces forearm fracture incidence in recent postmenopausal women – results of the Danish Osteoporosis Prevention Study. Maturitas, 36(3), 181–193.

[5] Santoro N. (2025). Understanding the menopause journey. Climacteric, 28(4), 384–388.

[6] Nejat, E. J., et al. (2010). Predictors of chronic disease at midlife and beyond–the health risks of obesity. Maturitas, 65(2), 106–111.

[7] Portman, D. J., et al. (2014). Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and the North American Menopause Society. Menopause, 21(10), 1063–1068.

[8] Canonico, M., et al. (2008). Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ, 336(7655), 1227–1231.

[9] Hodis, H. N., et al. (2016). Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. The New England journal of medicine, 374(13), 1221–1231.

[10] Scarabin, P. Y., et al. (2003). Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet, 362(9382), 428–432.

[11] Fournier, A., et al. (2005). Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. International journal of cancer, 114(3), 448–454.

[12] Academic Committee of the Korean Society of Menopause, et al. (2020). The 2020 Menopausal Hormone Therapy Guidelines. Journal of menopausal medicine, 26(2), 69–98.

About the Author

Anna Drangowska-Way

Anna graduated from the University of Virginia, where she studied genetics in a tiny worm called C. elegans. During graduate school, she became interested in science communication and joined the Genetics Society of America’s Early Career Scientist Leadership Program. After graduation, she worked as a freelance science writer and communications specialist mainly with non-profit organizations.

We are a non-profit foundation, and unlike some other organizations, we have no shareholders and no products to sell you. All our news and educational content is free for everyone to read, but it does mean that we rely on the help of people like you. Every contribution, no matter if it’s big or small, supports independent journalism and sustains our future.

News and Topics

(Placeholder for future news updates and topics)

Receive our Newsletter

Sign up to stay informed about the latest news and opportunities with LRI!

© 2025 Lifespan Research Institute – ALL RIGHTS RESERVED